EUVIMEDEUVIMED entdecken
Crossref

A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice

Panpan Zhang, Ke Wang, Tuo Hu, Menglong Xu, Xiangyan You, Manman Chen, Xuan Tang, Huajing Hu, Yiwei Jiang, Wenfeng Zhao, Shuhua Tan iD

The FASEB Journal · 2024

DOI: 10.1096/fj.202301564rr ↗

Kurz gefasst

Fachartikel in der Zeitschrift The FASEB Journal, 2024. Verfasst von Panpan Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cell and Molecular Biology, School of Life Science and Technology, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of…. Hauptthemen laut MEDLINE: Hyperlipidemias, Cardiovascular Diseases, Metabolic Diseases, Bacteriophages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 87 Literaturangaben. Gefördert von: National Fund for Major Projects of China, Nation Fund for Major Projects of China, Nation Funder for Major Projects of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dyslipidemia is characterized by elevated plasma levels of low‐density lipoprotein cholesterol (LDL‐C), triglycerides (TG), and TG‐rich lipoprotein (TGRLs) in circulation, and is closely associated with the incidence and development of cardiovascular disease. Angiopoietin‐like protein 3 (ANGPTL3) deficiency has been identified as a cause of familial combined hypolipidemia in humans, which allows it to be an important therapeutic target for reducing plasma lipids. Here, we report the discovery and characterization of a novel fully human antibody F1519‐D95aA against N‐terminal ANGPTL3 (NT‐ANGPTL3), which potently inhibits NT‐ANGPTL3 with a K D as low as 9.21 nM. In hyperlipidemic mice, F1519‐D95aA shows higher apolipoprotein B (ApoB) and TG‐lowering, and similar LDL‐C reducing activity as compared to positive control Evinacumab (56.50% vs 26.01% decrease in serum ApoB levels, 30.84% vs 25.28% decrease in serum TG levels, 23.32% vs 22.52% decrease in serum LDLC levels, relative to vehicle group). Molecular docking and binding energy calculations reveal that the F1519‐D95aA‐ANGPTL3 complex (10 hydrogen bonds, −65.51 kcal/mol) is more stable than the Evinacumab‐ANGPTL3 complex (4 hydrogen bonds, −63.76 kcal/mol). Importantly, F1519‐D95aA binds to ANGPTL3 with different residues in ANGPTL3 from Evinacumab, suggesting that F1519‐D95aA may be useful for the treatment of patients resistant to Evinacumab. In conclusion, F1519‐D95aA is a novel fully human anti‐NT‐ANGPTL3 antibody with potent plasma ApoB, TG, and LDL‐C lowering activities, which can potentially serve as a therapeutic agent for hyperlipidemia and relevant cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperlipidemiasCardiovascular DiseasesMetabolic DiseasesBacteriophagesHumansMiceAnimalsAngiopoietin-Like Protein 3Cholesterol, LDLAngiopoietin-like ProteinsMolecular Docking SimulationTriglyceridesApolipoproteins B

Stichwörter der Autor:innen

ANGPTL3DyslipidemiaEndothelial lipaseFully human antibodyLipoprotein lipase

Substanzen

Angiopoietin-Like Protein 3Cholesterol, LDLAngiopoietin-like ProteinsTriglyceridesApolipoproteins BANGPTL3 protein, human

Autor:innen und Institutionen

  • Department of Cell and Molecular Biology, School of Life Science and Technology, State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, China Pharmaceutical University,…

ORCID-Profile: Shuhua Tan

Förderung

  • National Fund for Major Projects of China
  • Nation Fund for Major Projects of China
  • Nation Funder for Major Projects of China
  • The Priority Academic Program Development of Jiangsu Higher Education Institutions
  • MOST | NSFC | National Fund for Fostering Talents of Basic Science
  • China Pharmaceutical University "Double First-Class"

Zitieren

APA

Zhang, P., Wang, K., Hu, T., Xu, M., You, X., Chen, M., Tang, X., Hu, H., Jiang, Y., Zhao, W., & Tan, S. (2024). A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice. The FASEB Journal. https://doi.org/10.1096/fj.202301564rr

Vancouver

Zhang P, Wang K, Hu T, Xu M, You X, Chen M, et al. A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice. The FASEB Journal. 2024. doi:10.1096/fj.202301564rr

BibTeX
@article{Zhang2024,
  author = {Zhang, Panpan and Wang, Ke and Hu, Tuo and Xu, Menglong and You, Xiangyan and Chen, Manman and Tang, Xuan and Hu, Huajing and Jiang, Yiwei and Zhao, Wenfeng and Tan, Shuhua},
  title = {A novel fully human anti‐NT‐ANGPTL3 antibody from phage display library exhibits potent ApoB , TG, and LDL‐C lowering activities in hyperlipidemia mice},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202301564rr}
}
Kostenlos starten →